01 — At a Glance
The Boring Pharma Play That’s Suddenly Not Boring
- 52-Week High / Low₹1,021 / ₹608
- TTM Revenue₹1,497 Cr
- TTM PAT₹132 Cr
- Full-Year EPS (TTM)₹23.1
- Q3 FY26 EPS₹7.37
- Book Value₹178
- Price to Book4.0x
- Dividend Yield0.28%
- Debt / Equity0.33x
- Interest Coverage13.4x
The Setup: Innova Captab Q3 FY26 delivered ₹450 crore revenue (+42.3% YoY), ₹42.1 crore PAT, and announced both UK-MHRA approval for Baddi cephalosporin manufacturing AND successful commercial ramp at the Jammu facility (which generated ₹89 crore in the quarter, up from ₹60 crore in Q2). The stock is at ₹714, up 14% from lows but still 30% off its 52-week high. Trading at 30.8x P/E. This is a growth story with a capex cycle hiding inside. Some people are noticing.
02 — Introduction
The Company That Makes Medicines Your Medicine Company Outsources To
Innova Captab is a pharma company. But not the kind that sells Dolo-650 to your local chemist every time you sneeze. They’re a contract development and manufacturing organisation — a CDMO. In English: big pharma companies and Indian drug makers send them raw materials, Innova Captab converts them into finished pills and capsules, and ships them back as someone else’s product. You’ve never heard of Innova Captab, but you’ve swallowed their output.
They work with Cipla, Glenmark, Indoco, Lupin, Ajanta — basically 14 of India’s top 15 pharma firms. About 80% of their CDMO customers have stuck around for 5+ years, which in contract manufacturing is equivalent to a marriage in Mumbai — unexpected, but when it lasts, it means something.
The company also runs its own branded generics business (selling under brands like Univentis) to ~220,000 pharmacy touchpoints, and exports branded generics to 25+ countries. Then there’s Sharon — a subsidiary they acquired in 2023 that does API manufacturing and serves regulated markets like Canada, UK, and Europe. Multiple legs. Multiple revenue streams. Multiple reasons to pay attention.
FY25 topped out at ₹1,249 crore revenue. Q3 FY26 posted ₹450 crore. The growth is real. The capex cycle just started. And management is now guiding 20% YoY company-level growth for FY27 on the back of Jammu facility ramp-up and continued CDMO expansion. No hypergrowth — just the mathematics of a plant that cost ₹450+ crore finally earning its keep.
The Concall Reality (Feb 2026): Management didn’t guide FY26 full-year numbers. They did say Jammu will hit ₹270–280 crore revenue in FY26, “possibly slightly overshooting.” They also admitted Jammu is not yet PAT-positive: “We have not contributed any PAT or EBITDA margin from the Jammu facility” — because depreciation eats into profits even as revenue grows. This is classic capex-cycle purgatory.
03 — Business Model: WTF Do They Even Do?
Three Legs. One Bad Metaphor. Infinite Pill-Making.
Innova Captab runs three distinct business verticals, each with its own economics and customer base.
Leg 1: CDMO (Contract Development & Manufacturing) — This is the workhorse. Q3 FY26 CDMO revenue hit ₹298.7 crore (+29% YoY). Management reckons volume growth was ~6–10% YoY, with the rest coming from product mix and customer wins. They serve 14 big-ticket customers who collectively generate 84% of CDMO revenue and have zero plans to leave. Low-volatility, high-loyalty, decent-margin business. It’s not sexy, but it’s the pillar.
Leg 2: Branded Generics (Domestic + International) — Q3 FY26 hit ₹151.6 crore (+79% YoY). This includes their own brands (Univentis in India, Sharon exports to regulated markets). They’ve built ~220,000 pharmacy touchpoints in India. Management is “aggressively expanding both domestic and international.” Translated: they’re plowing margin dollars into market share. Higher growth, higher volatility, lower margins. Fair trade-off for a company that’s learning to scale.
Leg 3: Sharon (Subsidiary) — Acquired in 2023, Sharon does API and formulation manufacturing for regulated markets. Contributing margin improvement and export diversification. Management bundles this under branded generics for disclosures, so precise numbers are hard to extract, but it’s clearly adding heft to international performance.
Exports now run at ~35% of Q3 revenue, versus ~25–27% a year ago. Management said their long-term comfort zone is 35% exports / 65% domestic. They’re basically there.
CDMO Revenue₹299 CrQ3 FY26 (66%)
Branded Generics₹152 CrQ3 FY26 (34%)
Export Mix35%Up from 26% YoY
On API Pricing (Management’s Actual Quote from Concall): “Year-on-year… we are even losing on the price front” for APIs. But QoQ stabilization is visible. Management refused to forecast further: “Prediction about the future is still uncertain.” Translation: if APIs spike again, margins get crushed. If they stabilize, they’ve got 15% EBITDA margin runway. Hedge your bets accordingly.
💬 If you’re a pharma investor, do you want exposure to CDMO upside or branded generics expansion? Or are both too risky in a capex cycle? Drop your thoughts below!
04 — Financials Overview
Q3 FY26: The Numbers That Actually Matter
Result type: Quarterly Results | Q3 FY26 EPS: ₹7.37 | Annualised EPS (Q3×4): ₹29.48 | TTM EPS: ₹23.1
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 450 | 316 | 380 | +42.3% | +18.4% |
| Operating Profit (EBITDA) | 71.1 | 50.8 | 52.0 | +39.8% | +36.9% |
| EBITDA Margin % | 15.8% | 16.1% | 13.7% | -30 bps | +210 bps |
| PAT | 42.1 | 34.2 | 29.8 | +23.1% | +41.3% |
| EPS (₹) | 7.37 | 5.98 | 5.18 | +23.2% | +42.3% |
The Setup: Q3 FY26 revenue ₹450 crore is +42% YoY. EBITDA at ₹71.1 crore is +40% YoY. PAT at ₹42.1 crore is +23% YoY (slightly lagging due to depreciation and interest costs from Jammu capex). The QoQ jump in PAT (+41%) is particularly spicy — that’s operating leverage kicking in as Jammu ramps and fixed costs get absorbed over higher revenue. Management’s own commentary: they maintained “around 15% (+/- 2%)” EBITDA margins, with 9M FY26 margins at 15.5%. The TTM EPS calculates to ₹23.1, making the stock P/E 30.8x. Is that cheap for a company growing 40%? Depends on how long the growth lasts.
From the Concall (Mgmt. Says): “We always maintain our margin profile at, say, 15% (+/- 2%).” This is not a guidance. This is a historical posture statement. It means they’re disciplined about EBITDA, but also willing to invest back into growth initiatives even if it temporarily hits PAT. Jammu is that growth initiative. Once it’s accretive (which mgmt. says happens next year), the “15% margin + growth” combination changes the valuation conversation.
05 — Valuation Discussion: Fair Value Range
What’s This Company Actually Worth?
Method 1: P/E Based
Annualised Q3 EPS = ₹29.48. Pharma peers trade at 20x–35x P/E (Sun Pharma: 35.5x, Divi’s Lab: 64.6x, Torrent: 62.8x, Dr Reddy’s: 19.4x). Innova’s growth + CDMO-led earnings justify 22x–28x P/E band (accounting for capex cycle and margin stability).
Range: ₹649 – ₹824
Method 2: EV/EBITDA Based
TTM EBITDA = ~₹221 crore (9M ₹183.7 cr + Q4 proxy). Current Enterprise Value = ₹4,364 cr. Current EV/EBITDA = 19.8x. Quality pharma / CDMO peers trade at 12x–20x. Fair range: 14x–18x, accounting for capex normalization post-Jammu ramp.
EBITDA range (14x–18x): ₹3,094 Cr – ₹3,978 Cr → Per share:
Range: ₹540 – ₹695
Method 3: DCF Based
Base EBITDA: ₹221 cr (TTM). Growth: 15% for 3 years (post-Jammu inflection), 10% for 2 years. Terminal growth: 4%. WACC: 10%.
→ PV of 5-year FCFs at 10%: ~₹1,850 Cr
→ Terminal Value (4% growth / 6% cap rate): ~₹4,680 Cr
→ Total EV: ~₹6,530 Cr (net debt ~₹271 Cr)
Range: ₹688 – ₹832
Fair Min: ₹540
CMP: ₹714
Fair Max: ₹832
⚠️ EduInvesting Fair Value Range: ₹540 – ₹832. CMP ₹714 sits comfortably within the range. This range assumes Jammu ramps as guided, API pricing stabilizes, and management executes on 20% FY27 growth guidance. This fair value range is for educational purposes only and is not investment advice. Please consult a SEBI-registered investment advisor before making any financial decision.
06 — What’s Cooking: News, Triggers & Drama
The Plot Twists in the Pill Box
